Chris Boland - Avivagen Insider

VIV -- Canada Stock  

CAD 0.65  0.05  7.14%

CFO

Mr. Chris Boland was appointed as Chief Financial Officer of Avivagen Inc., with effect from July 12, 2012
  CFO Since 2012      
613-949-8164  http://www.avivagen.com
Boland is a Canadian chartered accountant and also holds the certified management accountant designation. Prior to his present appointment, Mr. Boland was in public practice . Earlier positions at other organizations include general manager at Canada Post Corporationrationrationration, chief financial officer and vicepresident finance at Optiwave Corporationrationrationration, director of tax and treasury, controller, at Eftia OSS, manager of financial reporting and controller at the Canadian Bank Note, and manager of financial reporting at Mitel Corporationrationrationration. He was also an auditor at the Office of the Auditor General and manager at Treasury Board.

Management Efficiency

The company has return on total asset (ROA) of (57.97) % which means that it has lost $57.97 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (312.77) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 1.22 M in total debt with debt to equity ratio (D/E) of 45.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Avivagen has Current Ratio of 5.93 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Found 5 records

CFO Since

Sean McGuckinThe Bank of Nova Scotia
2015
Riaz AhmedThe Toronto Dominion Bank
2016
Alister CowanSuncor Energy
2014
Rod BolgerRoyal Bank of Canada
2016
Janice FukakusaRoyal Bank of Canada
2009

Entity Summary

Avivagen, Inc. develops and commercializes various products to replace antibiotics in livestock feeds to optimize the health and growth of the animals by supporting the animals own health defenses. The company was formerly known as Chemaphor, Inc. and changed its name to Avivagen, Inc. in May 2012. Avivagen is traded on TSX Venture Exchange in Canada.Avivagen (VIV) is traded on TSX Venture Exchange in Canada. It is located in 100 Sussex Drive and employs 19 people.

Avivagen Leadership Team

David Hankinson, Director
Louis Hui, Director
Chris Boland, CFO
David Allan, Director
Amin Khalifa, Director
Aubrey Dan, Director
Cameron Groome, CEO
Vanessa Grant, Director
Andrew Basek, Director, MBA
Drew Basek, Director, MBA
Paul Mesburis, Director
Graham Burton, Director, Ph.D
G Anthony, Director

Stock Performance Indicators

Current Sentiment - VIV

Avivagen Investor Sentiment
Most of Macroaxis users are at this time bullish on Avivagen. What is your sentiment towards investing in Avivagen? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip
Also Currentnly Active
Purchased over 100 shares of
over a week ago
Traded for 10.44
Purchased over 300 shares of
over a week ago
Traded for 6.24
Purchased over 70 shares of
over a week ago
Traded for 23.42
Also please take a look at World Market Map. Please also try Analyst Recommendations module to analyst recommendations and target price estimates broken down by several categories.